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Abstract
Background: Solid tumours are less oxygenated than normal tissues. Consequently, cancer cells acquire to be
adapted to a hypoxic environment. The poor oxygenation of solid tumours is also a major indicator of an adverse
cancer prognosis and leads to resistance to conventional anticancer treatments. We previously showed the
involvement of Che-1/AATF (Che-1) in cancer cell survival under stress conditions. Herein we hypothesized that
Che-1 plays a role in the response of cancer cells to hypoxia.
Methods: The human colon adenocarcinoma HCT116 and HT29 cell lines undepleted or depleted for Che-1
expression by siRNA, were treated under normoxic and hypoxic conditions to perform studies regarding the role of
this protein in metabolic adaptation and cell proliferation. Che-1 expression was detected using western blot assays;
cell metabolism was assessed by NMR spectroscopy and functional assays. Additional molecular studies were
performed by RNA seq, qRT-PCR and ChIP analyses.
Results: Here we report that Che-1 expression is required for the adaptation of cells to hypoxia, playing an
important role in metabolic modulation. Indeed, Che-1 depletion impacted on HIF-1α stabilization, thus
downregulating the expression of several genes involved in the response to hypoxia and affecting glucose
metabolism.
Conclusions: We show that Che-1 a novel player in the regulation of HIF-1α in response to hypoxia. Notably, we
found that Che-1 is required for SIAH-2 expression, a member of E3 ubiquitin ligase family that is involved in the
degradation of the hydroxylase PHD3, the master regulator of HIF-1α stability.
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Background
Hypoxia, i.e. low levels of O2, is a common feature of solid
tumours, which leads to an aggressive tumor phenotype.
Hypoxia is also associated with resistance to therapeutic
treatments and with a poor clinical prognosis [1]. The
main adaptation of tumor cell to hypoxia is the switch
from an aerobic metabolism to glycolysis [2].
The glycolytic pathway produces only 2 ATP (adeno-
sine triphosphate) per molecule of glucose, but cancer
cells compensate this reduced yield in ATP production
increasing, by approximately ten fold the glycolytic flux
of glucose to pyruvate, and then to lactate [3]. Glycolysis
also provides precursors for the synthesis of nucleic
acids, lipids and amino acids that are crucial to enhance
survival and growth of cancer cells both during carcino-
genesis, and in metastatic tumours [4, 5].
The master regulator of hypoxia response is the hyp-
oxia inducible factor (HIF) family of transcription fac-
tors, in particular HIF-1α [6]. Indeed, in low oxygen
tension HIF-1α is quickly stabilized and affects most of
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the cancer hallmarks involved in the hypoxic response [6].
This transcription factor regulates the expression of mul-
tiple genes involved in proliferation, apoptosis, immune re-
sponse, genomic instability, pH homeostasis, invasion and
metastasis [6] so that, as a rule, over-expression of HIF-1α
is associated with a poor clinical outcome [7, 8]. HIF-1α ex-
pression is mainly regulated through oxygen-dependent
proteosomal degradation. Under normoxic conditions, spe-
cific prolyl-hydroxylase domain proteins (PHD) hydroxyl-
ate HIF-1α, at one or both conserved prolyl residues,
promote the binding of HIF-1α to the von Hippel Lindau
protein (pVHL)-E3-ubiquitin ligase complex and then con-
sequently its ubiquitination and degradation [9]. The inhib-
ition of PHD enzymes by specific molecules leads to
stabilization of HIF-1α, and constitutes a valid therapeutic
approach in treating conditions of tissue stress, like inflam-
matory or ischemic events [10]. Importantly, under hypoxic
conditions HIF-1α activity contributes to shift cell glucose
metabolism from oxidative to glycolytic, by increasing the
expression of glucose transporters (SLC2A1 and SLC2A3)
and downstream glycolytic enzymes, making glycolysis the
main source of energy in hypoxic cells [11, 12].
Several studies have been conducted to investigate how
to reduce the ability of cells adapting to hypoxic condi-
tions, where HIF-1α has emerged to be an attractive target
for new anti -cancer therapies to improve the current
treatments of metastatic and resistant cancers [13].
Che-1/AATF (Che-1) is a RNA polymerase II-binding
protein mainly involved in different and fundamental pro-
cesses in controlling transcription, cell cycle regulation,
DNA damage response, and apoptosis [14]. This protein is
regulated by several post-translational modifications, and
in response to several kinds of stress, Che-1 not only acti-
vates p53 expression, but it also binds this onco-suppressor
in such way that it represses the apoptotic arm of the p53
response [15, 16]. Moreover, Che-1 sustains mutant p53
expression, contributing to the growth of tumor cells [17].
More recently, Che-1 was found to be phosphorylated in
response to several stresses, regulating mTORC1 and
mTORC2 activity and activating autophagy, thus providing
a new link between different cellular stress factors and
mTOR signalling [18]. In this study, we explored the role
of Che-1 in hypoxic response. We found that Che-1 ex-
pression is required for the adaptation of cancer cells to
hypoxia. In particular, our results demonstrated that Che-1
depletion in the presence of hypoxia strongly reduces
metabolic adaption and induces cell death. Taken together
these findings reinforce the notion that Che-1 could be an
attractive target for cancer therapy.
Methods
Cell line and culture conditions
HCT116 colon cancer cells were cultured in Dulbecco’s
Modified Eagle Medium High Glucose (DMEM), HT29
and A549 cancer cell lines in RPMI 1640, supplemented
with 10% fetal bovine serum (FBS). Cells were plated in
60 or 100 mm2 dishes and maintained at 37 °C in a
humidified atmosphere of 5% CO2–95% air. For hypoxia
treatments, cell culture dishes were exposed to a mix of
1% O2 saturated with 5% CO2 and 94% N2 for the time
indicated, using hypoxia modulator chamber (Billups-
Rothenberg). The temperature in the anaerobic chamber
was set at 37 °C. The pH in the cell culture medium was
determinated by CyberScan pH 510 Bench pH/mV
Meter with ATC probe, integral electrode holder &
power adapter (Thermofisher).
Transfections, western blot analysis and antibodies
Che-1 siRNA was performed by transfecting a specific
pool of double-stranded RNA oligonucleotides (siChe-1)
(Stealth, Life Technologies-Thermofisher). Stealth siRNA
Negative Control oligos were purchased from Life Tech-
nologies (Thermofisher). Transfections were carried out
by Lipofectamine 3000 (Life Technologies-Thermofisher)
in accordance with the manufacturer’s instructions.
Cell extract purifications and western blotting analyses
were performed as previously described [18] by using
the following antibodies: anti-Che-1 [19], anti-β-actin
(Sigma, A5441, clone AC-15); anti-HIF-1α (BD Trans-
duction Laboratories-610958); anti-HIF-1α (Bethyl La-
boratories A300-286A); anti-Caspase-7 (Cell Signaling
Technologies-12827); anti-EGLN3/PHD3 (Novus Biologi-
cals NB100-139); anti-SIAH-2 (N14) (Santacruz sc-5507).
Densitometric analyses of immunoblots were performed
using Alliance system by UVITECH Cambridge, and Ra-
tios were calculated by the following formula:
intensity sample/intensity β Actin
intensity control/intensity β Actin
Assay of oxygen consumption
Cells were plated in 15 cm2 dishes and after 24 h they
were transfected by specific siRNA. Then, the cells were
exposed to hypoxia for 16 h. At the end of incubation,
cells were trypsinized and suspended in DMEM at a
concentration of 1 × 108/ml. Oxygen consumption was
measured with a Clark oxygen electrode (Yellow Spring
Instruments Company) at 37 C°; the concentration of
dissolved oxygen was taken to be 406 ng-atoms O/ml
[20]. The rate of oxygen consumption was determined
by adding 0.1 ml of cell suspension (1 × 107 cells) to
1.9 ml of DMEM in a closed glass chamber of 2 ml cap-
acity (Gilson Medical Electronics). The final concentra-
tions of oligomycin, FCCP and antimycin A were
respectively, 1 μg/ml, 0.25 μM, and 2 μM.
Hexokinase activity assay
Cells were transfected with siControl or siChe-1, and
after hypoxia treatment collected and processed. Cells
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were lysed and the activity of the Hexokinase was mea-
sured in accordance with the Hexokinase Assay Kit
protocol (Cat# E-111) from Biomedical Research Service
Center, using a SpectraMax M2 MultiMode Microplate
Reader (Molecular Devices, Sunnyvale, CA, USA), with
OD 492 nm. The activity was calculated in IU/L unit.
Chromatin immunoprecipitation assay (ChIP)
Chromatin immunoprecipitation assays in HCT116 cells
were performed as previously described [17], by using
anti-HIF-1α (Bethyl). Immunoprecipitations with no
specific immunoglobulins (Santa Cruz) were performed
as negative controls. For quantitative ChIP analysis
(ChIP-qPCR), 1ul of purified DNA was used for amplifi-
cation on an Applied Biosystems 7500 Fast Real Time
PCR system (with Applied Biosystem SYBR GREEN).
The following human promoter-specific primers were
employed in PCR amplifications:
PDK1 forward 5′- GAGCCTTTTGGCTGAGATTG -3′
PDK1 reverse 5′- GATGGGACTGGGGACACTAA -3′
PFKFB4 forward 5′- CCCTAGCAAGGAGGTAGCAG -3′
PFKFB4 reverse 5′- AGGCCAGGATCGAGAATGCG -3′
RNA isolation and quantitative RT–PCR analysis
Total RNA was isolated using TRIzol reagent (Life
Technologies-Thermofisher) in accordance with the
manufacturer’s instructions, and the first-strand cDNA
was synthesized with random primers and M-MLV re-
verse transcriptase (Life Technologies-Thermofisher).
The cDNA was used for quantitative real-time PCR
(qRT–PCR) experiments carried out in a 7500 Fast Real
Time PCR System (Applied Biosystem-Thermofisher)
using SYBR GREEN PCR Master Mix (Applied Biosystem-
Thermofisher). ΔΔCt values were normalized with those
obtained from the amplification of the endogenous RPL19
gene. Data are presented as the mean ± SD from three
independent experiments performed in duplicate. The
following human-specific primers were employed in
PCR amplifications:
RPL19 forward 5′-CGGAAGGGCAGGCACAT -3′
RPL19 reverse 5′- GGCGCAAAATCCTCATTCTC -3′
Che-1 forward 5′- CCGGAATTCGGATAAGACCAA
ACTGGCT -3′
Che-1 reverse 5′- CCGCTCGAGGAGTTCTCGAAG
GAGCTG -3′
SLC2A1 forward 5′- GTGGGAGGAGCAGTGCTT
GG -3′
SLC2A1 reverse 5′- GACGATGCCCAGCTGGTGCA -3′
SLC2A3 forward 5′- TGCGGGGTGCCTTTGGCACT -3′
SLC2A3 reverse 5′- TGGGCTGTCGGTAGCTGGAC -3′
PFKFB4 forward 5′- GCGCATTGAGTGCTATGAGA -3′
PFKFB4 reverse 5′- AATATACGATGCGGCTCTGG -3′
PDK1 forward 5′- GCCCAGGGTGTGATTGAATA -3′
PDK1 reverse 5′- GGACTTCCTTTGCCTTTTCC -3′
SIAH-2 forward 5′- CATCAGGAACCTGGCTAT -3′
SIAH-2 reverse 5′- GGACGGTATTCACATATG -3′
PHD3 forward 5′- TCCCTGGGCTGGACTGACCT
TT -3′
PHD3 reverse 5′- CCTCCCCCAAGAAGCCACTGA
AA -3′
HIF1-α forward 5′- CCAGTTAGGTTCCTTCGATCA
GT -3′
HIF1-α reverse 5′- TTTGAGGACTTGCGCTTTCA -3′
1H-NMR Spectroscopy
Each medium sample (2 ml) was lyophilized and then dis-
solved in 700 μl of 1 mM TSP [sodium salt of 3 (tri-
methylsilyl) propionic-2,2,3,3-d4 acid], 10 mM sodium
azide D2O phosphate buffer solution (pH = 7.4) and finally
homogenized by vortex mixing for 1 min. After centrifu-
gation (10 min, 10.000 RCF at 22 °C), 600 μl of each
resulting supernatant was transferred to a 5-mm NMR
tube and used for the NMR analysis2D. 1H J-resolved
(JRES) NMR spectra were acquired on a 500 MHz Varian/
Agilent spectrometer (Agilent, Santa Clara, CA) using a
double spin echo sequence with 4 transients per incre-
ment for a total of 32 increments. These were collected
into 16 k data points using spectral widths of 6 kHz in F2
and 40 Hz in F1. There was a 2.0 s relaxation delay. Each
FID was Fourier transformed after a multiplication with
sine-bell/exponential function in the F2 dimension and a
sine-bell function in the F1 dimension. JRES spectra were
tilted by 45°, symmetrised about F1, referenced to TSP at
δH= 0.0 ppm and the proton-decoupled skyline projec-
tions (p-JRES) exported using Agilent VNMRJ 3.2 soft-
ware. Metabolites responsible for the separation between
samples from cells treated with hypoxia in the presence or
absence of siChe-1 were identified using an in-house
NMR database and Chenomx NMR suite v. 7.7 (Chenomx
Inc., Alberta, Canada).
NMR spectra pre-processing treatment
The 1D skyline projections exported were aligned and
then reduced into spectral bins with widths ranging
from 0.01 to 0.02 ppm by using the ACD intelligent
bucketing method (1D NMR Manager software (ACD/
Labs, Toronto, Canada). To compare the spectra, the in-
tegrals derived from the binning procedure were nor-
malized to the total integral region, following exclusion
of bins representing the residual water peak (δ 4.33–
5.17 ppm) and the TSP peak (δ 0.5–0.5 ppm). The
resulting data was used as input for Principal Compo-
nent Analysis (PCA) [21] and was performed by using
SIMCA-P + version 12 (Umetrics, Umea, Sweden).
RNA-Seq
HCT116 cell line was transfected with siChe-1 or siRNA
negative control using Lipofectamine 3000 (Stealth Life
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Technologies-Thermofisher), and exposed to hypoxia for
4 h where indicated. Total RNA was extracted from cells
using Trizol (Life Technologies-Thermofisher), purified
and enriched by Qiagen RNeasy columns for gene ex-
pression profiling (Qiagen). Quantity and integrity of the
extracted RNA were assessed by NanoDrop Spectropho-
tometer (NanoDrop Technologies) and by Agilent 2100
Bioanalyzer (Agilent Technologies), respectively. RNA li-
braries for sequencing were generated in accordance
with the standard Illumina TruSeq RNA Library Prep
Kit protocol using 2 μg total RNA as starting material.
The resulting library was controlled qualitatively with
the High Sensitivity DNA Kit (Agilent Technologies,
Santa Clara, CA, USA) and quantitatively with real-time
analysis employing a SYBR Green qPCR protocol with
specific primers complementary to adapter sequences.
Based on the qPCR quantification, libraries were nor-
malized to 1 nM and denatured by using 0.1 N NaOH.
Cluster amplification of denatured templates was carried
out according to the manufacturer’s protocol (Illumina,
Inc., San Diego, CA, USA). Sequencing was performed
on a Genome Analyzer IIx (Illumina) in paired-end
mode, sequencing from each side 51 bp. For each sam-
ple generated by the Illumina platform, a pre-process
step for quality control was performed to assess se-
quence data quality and to discard low quality reads.
Bioinformatic analysis
The analyses were performed by exploiting the RNA-seq
analysis workflow RAP [22] that comprises of read map-
ping, transcript assembly and abundancy estimation
followed by transcript-based differential expression via
the Tuxedo suite [23]. Paired-end reads were mapped to
the human genome assembly hg19 with TopHat and fur-
ther analyzed by the Cufflinks-Cuffdiff pipeline to iden-
tify differentially expressed genes. We ran the pipeline
without novel transcript discovery. Raw data (BAM files)
were submitted to the National Center for Biotechnol-
ogy Information (NCBI) Gene Expression Omnibus
database (http://www.ncbi.nlm.gov/geo), with accession
ID GSE90599. UCSC Genome Browser screenshots were
created through loading bigWig files generated from the
accepted_hits Tophat BAM file. Scatterplots were cre-
ated thanks to the CummeRbund library. Custom plots
such as barplots were created via custom R scripting.
Statistical analysis
Statistical analyses were performed by using the Student
two-tailed t-test to compare in vitro experiments. All
statistical tests were carried out using GraphPad Prism
version 5.0 for Windows, Graphpad Software, San Diego
California USA (www.graphpad.com). Probability value
of <0.05 was considered statistically significant.
Results
Che-1 protects colon cancer cells from apoptosis induced
by hypoxia
Over the last few years, Che-1 has been identified as a
protein involved in several cellular pathways including
the control of transcription and apoptosis [14]. In par-
ticular, several findings indicate that Che-1 is involved
not only in DNA damage response (DDR) but also in
other types of stress. Indeed, it has been more recently
documented that Che-1 protects cells from apoptosis in-
duced by ionizing radiation, glucose deprivation and
hypoxia, inducing autophagy by the control of the kinase
activity of mTOR [18]. In order to better investigate the
role of Che-1 in response to hypoxia, we exposed
HCT116 and HT29 colon cancer cells to low tension of
oxygen at different times. The hypoxic treatment at 4 h
induced, together with HIF-1α stabilization, an increase
of Che-1 levels (Fig. 1a) through its phosphorylation
[18], whereas apoptosis activation after 8 h, but mostly
after 16 h, induced a degradation of Che-1 as already ob-
served with other forms of stress (Fig. 1a). In addition,
we analyzed Che-1 mRNA levels, demonstrating that
hypoxia is able to regulate the expression of this gene
also at transcriptional level (Fig. 1b). In order to better
understand the involvement of Che-1 in hypoxia re-
sponse, we depleted Che-1 expression by a specific pool
of siRNA oligos. As shown in Fig. 1c and d, Che-1 deple-
tion significantly decreased cell viability, strongly in-
creasing apoptosis induction. Taken together these data
demonstrate that Che-1 levels are regulated by hypoxia,
and its expression is required for the cellular response to
this kind of stress.
Che-1 is required for metabolic adaption to hypoxia
It has been extensively demonstrated that the principal
mechanism by which the cell protects itself after hypoxia
is a switch of the glucose metabolism from mitochon-
drial respiration to glycolysis [2]. Based on the above-
mentioned considerations, we evaluated whether Che-1
depletion could affect this switch. The culture medium
of cells lacking Che-1 expression, placed in a hypoxic
environment rapidly becomes more acidic due to high
production of lactic acid, compared to control cells. As
shown in Fig. 2a, after 16 h of hypoxia, HCT116 siCon-
trol cells showed a much lower pH compared to the
cells under normoxic conditions (6,7 vs 7,40). On the
contrary, the pH level of Che-1 depleted cells after 16 h
of hypoxia was similar to normoxic cells (7,15 vs 7,40),
thus suggesting an involvement of Che-1 in this metabolic
switch. Similar results were obtained when we analyzed
two other cell lines (Additional file 1: Figures S1A and B).
To further investigate these findings, we analyzed by using
PCA 1H NMR spectra collected on medium samples from
HCT116 cells treated or untreated with hypoxia at
Bruno et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:32 Page 4 of 11
different times, in the presence or absence of siChe-1
(Fig. 2b). At an earlier time point, we only discerned a
significant metabolic difference between hypoxic and nor-
moxic samples (p < 0.0001 on PC1). Notably, after 4 hours
of hypoxic treatment, we observed that the metabolism of
Che-1 depleted cells was different from that of their hyp-
oxic and normoxic controls (p = 0.035 on PC2). Moreover,
at this time, we did not observe any significant differences
between the two groups of controls. As the experimental
times elapsed, the metabolic effects due to the depletion
of Che-1 became more evident: we observed metabolic
differences between samples from Che-1 depleted cells
and their control cells in hypoxic conditions at 8 h on
PC2 (p = 0.003) and at 16 h on PC1 and PC2 (p = 0.002).
It is important to note that the metabolism of Che-1 de-
pleted cells were very similar to that of their controls
under normoxic conditions. Indeed, the difference be-
tween Che-1 depleted cells in hypoxic condition and
control cells in normoxic condition did not result sig-
nificant at 8 h, resulting significant only at 16 h on
PC2 (p = 0.002). Conversely, the metabolic effects of
hypoxia were more evident on cells without depletion
of Che-1: the differences between controls in hypoxic
or normoxic conditions were evident at 8 (p = 0.010
on PC2) and 16 h (p = 0.016 on PC1 and p = 0.003 on
PC2). These results were further confirmed by analyzing
HT29 and A549 cells (Additional file 1: Figures S1C and
D). Subsequently, in order to identify the main metabolites
contributing to the discrimination between Che-1 de-
pleted cells and their control in hypoxic conditions at 16 h
on PC1, we analyzed the loadings values from PCA with a
threshold of 0.95. PC1 included the following variables
with the highest correlation levels: glucose with positive
loadings and lactate with negative loadings. Therefore,
considering the net balance of these metabolites, PC1 in-
dicates that the depletion of Che-1 induced a lower con-
sumption of glucose as well as a lower production of
lactate (Fig. 2c). The reduced production of lactate in
Che-1 depleted cells were further confirmed in HT29 cells
(Additional file 1: Figure S1E). Moreover, the absence of a
Fig. 1 Che-1 is involved in the response to hypoxia. a Western blot (WB) analysis performed with the indicated antibodies (Abs) of total cell
extracts (TCEs) from HCT116 or HT29 cells exposed to hypoxia (1% O2) for the times indicated. b Quantitative RT–PCR (qRT–PCR) performed in
HCT116 cells exposed to hypoxic conditions as in a. Values were normalized to RPL19 expression. Bars represent the standard error of three
different experiments. *P≤ 0,02, **P ≤ 0.002. c HCT116 and HT29 cells were transiently transfected with Stealth siRNA negative control (siControl)
or siRNA Che-1 (siChe1) and treated as in a. Cell proliferation was measured by counting the cells daily. A representative histogram is depicted
utilizing values from three independent experiments and significance was calculated. *P ≤ 0.02, **P = 0.0005, ***P = 0.0008, ****P ≤ 0,0001, n.s., not
significant. d WB analysis with the indicated Abs of TCEs from HCT116 and HT29 cells transiently transfected and treated as in c
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significant variation in the consumption of glutamine be-
tween HCT116 cells under hypoxic conditions with or
without depletion of Che-1 suggested that the significant
difference in lactate production was only correlated to glu-
cose consumption, and therefore that Che-1 depletion de-
creases the glycolytic phenotype of HCT116 cells under
hypoxic conditions. These findings were confirmed by an
increase of oxygen consumption (Fig. 2d), and a decrease
in Hexokinase (HK) activity (Fig. 2e), in cells depleted for
Che-1. Taken together, these results demonstrate an im-
portant role of Che-1 in the metabolic adaptation in re-
sponse to hypoxic stress.
Che-1 modulates genes involved in the response to
hypoxia
Since Che-1 is an important transcriptional co-factor, we
wondered whether this protein regulated glucose metabol-
ism by affecting the transcriptional activation in response
to hypoxia. To address this hypothesis, we performed a
whole transcriptome sequencing (RNA-seq) analysis in
HCT116 cells treated or untreated with hypoxia, in the
presence or absence of Che-1 expression. Differential
Gene Expression analysis with standard parameters (cor-
rected p-value < 0.05) showed 38 modulated genes after
4 h of hypoxia treatment (Fig. 3a), and as expected, Gene
Ontology analysis of these genes revealed a strong enrich-
ment of several gene clusters related to cellular metabolic
processes (Fig. 3b). Among them, we observed that Che-1
depletion was able to modulate genes playing a key role in
glucose transport (SLC2A1 and SLC2A3) and glucose
metabolism (PFKFB4, PDK1, PHD3) (Fig. 3d-e-f and
Additional file 2: S2A). Notably these genes are finely reg-
ulated by HIF-1α in response to hypoxia [11–25]. This ob-
servation prompted us to evaluate whether Che-1 could
affect HIF-1α recruitment onto the promoters of these
target genes. To do this, we performed ChIP experiments,
Fig. 2 Che-1 is involved in the metabolic switch in response to hypoxia. a HCT116 cells were transiently transfected with stealth siRNA negative
control (siControl) or siRNA Che-1 (siChe-1) and exposed to hypoxia for 16 h where indicated and pH was measured. b Score plots indicating
metabolic differences between hypoxic and normoxic samples from HCT116 cells transiently transfected as in a and exposed to hypoxia for the
times indicated. c Glucose, lactate and glutamine levels in HCT116 cells transiently transfected as in a and exposed to hypoxia for the indicated
times. The levels are the means ± S.D. of four independent experiments p < 0.05). d-e HCT116 cells were treated as in A and Oxygen consumption
(d) and HK activity (e) were measured. Values are mean of three independent experiments. *p < 0.05 (d) *p < 0.05, n.s., not significant (e)
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immunoprecipitating HIF-1α in cells depleted or not for
Che-1 and exposed to hypoxia. In absence of Che-1
expression, the analysis of PDK1 and PFKFB4 promoters,
revealed a strong decrease of HIF-1α recruitment, thus
confirming an involvement of Che-1 in HIF-1α activity
(Fig. 3f). Taken together, these results provide strong evi-
dence that Che-1 is required by HIF-1α to regulate target
genes involved in metabolism.
Che-1 promotes the degradation of HIF-1α through the
transcriptional regulation of the RING E3 ubiquitin ligase
SIAH2
Next, we attempted to shed light on the mechanism/s by
which Che-1 exerts its activity on HIF-1α functions. For
this purpose, we initially tested the possibility of a phys-
ical interaction between these proteins, but immunopre-
cipitation experiments did not show any binding
between them (data not shown). Therefore, we examined
whether Che-1 was able to regulate HIF-1α expression
in HCT116 and HT29 cells undepleted or depleted for
Che-1, and exposed them to hypoxia at different times.
As shown in Fig. 4a, HIF-1α expression was undetect-
able under normoxic conditions, but its protein levels
markedly increased during hypoxic treatment, where in-
stead in Che-1 depleted cells this phenomenon was
strongly reduced. The analysis of HIF-1α mRNA expres-
sion under the same conditions revealed that, unlike the






Fig. 3 Che-1 regulates genes transcription in response to hypoxia. a Intensity Heatmap of modulated genes in HCT116 cells after 4 h of exposure
to hypoxia highlighted by red frame. b Gene Ontology from Enrichr [42]. Calculated from the most significant (corrected P <0.05) 38 genes
regulated in Cuff diff analysis, Normoxic cells VS Hypoxic cells. c Expression levels in HCT116 cells transiently transfected with Stealth siRNA
negative control (siControl) or siRNA Che-1 (siChe-1) and exposed to hypoxia for 4 h. Gene expression levels are reported as FPKM reconstructed
from Cufflinks RNA-Seq analysis. d Genome Browser screenshot of Big Wig Enrichment from RNA-Seq BAM files, showing expression of SLC2A1
(right) and SLC2A3 (left) genes in HCT116 cells transiently transfected with Stealth siRNA negative control (siControl) or siRNA Che-1 (siChe-1) and
exposed to hypoxia for 4 h. e Quantitative RT–PCR (qRT–PCR) for metabolic genes expression was performed in HCT116 cells transiently transfected
and treated as in c. Values were normalized to RPL19 mRNA expression. Error bars represent the standard error of three different experiments.
*P≤ 0,006, **P≤ 0.008, ***P≤ 0.0008. f ChIP-qPCR analysis of HCT116 cells transfected with siControl or siChe-1 exposed to hypoxia, using anti-HIF-1α
Ab or control IgGs. Error bars represent the standard error of three different experiments. *P≤ 0.004, **P = 0.0005
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significant decrease of HIF-1α transcription in Che-1 de-
pleted cells (Fig. 4b), suggesting the presence of another
mechanism for its regulation. HIF-1α is a central regula-
tor of the cellular response to hypoxia, and its expres-
sion is strongly regulated through prolyl-hydroxylation
by PHD enzymes required for its degradation. In par-
ticular, PHD3 exhibits high affinity to hydroxylase HIF1α
[26]. This enzyme is also a target of HIF-1α and its ex-
pression is regulated in response to hypoxia [27–29].
Notably, Che-1 depletion induced a significant increase
of PHD3 in cells exposed to hypoxia, in agreement with
the observed decrease of HIF-1α levels (Fig. 4a–c). Thus,
we analyzed the regulation of PHD3 expression in re-
sponse to hypoxic treatments. Since RNA–Seq analysis
demonstrated that PHD3 mRNA expression is in fact in-
creased by hypoxic conditions and Che-1 depletion in-
duces a reduction of its/this activation (Fig. 3d–f ), we
evaluated if Che-1 could exert its activity at the post-
transcriptional level. In attempting to characterize this
phenomenon, we focused our attention on the RING
finger E3 ligase SIAH, a family proteins able to induce
the ubiquitination and degradation of a several
substrates, regulating in this way, different pathway and
numerous biological processes. SIAH2 like other ubiqui-
tin ligases can promote its own degradation and it is
generally present at very low levels in cells generating
many problems to detect the levels of this protein [30–
32]. Previous work demonstrated that SIAH2 is also able
to modulate PHD3 level in response to hypoxia, affects
its stability [30]. As shown in Fig. 4d, in hypoxic condi-
tion, Che-1 depletion produced a decrease of SIAH-2
mRNA expression, indicating that the transcription of
this gene is modulated by Che-1 activity. These results
were confirmed by a qRT-PCR analysis, showing a de-
crease of the levels of SIAH-2 transcript concomitantly
to Che-1 inhibition (Fig. 4e). Collectively, these findings
demonstrate that Che-1 plays an important role in HIF-
1α stabilization, consequently strongly affecting metabol-
ism regulation in response to hypoxia.
Discussion
In response to hypoxia, the cell has devised numerous
adaptation strategies enabling it to survive. These mecha-
nisms are mainly implemented at transcriptional level,
Fig. 4 Che-1 modulates HIF-1α protein expression. a WB analysis with the indicated Abs of TCEs from HCT116 and HT29 cells transiently transfected
with stealth siRNA negative control (siControl) or siRNA Che-1 (siChe-1) and exposed to hypoxia where indicated. b qRT–PCR performed in HCT116
cells transiently transfected and treated as in a. Values were normalized to RPL19 mRNA expression. Error bars represent the standard error of three
different experiments. *P≤ 0,02, **P≤ 0.01. c WB analysis with the indicated Abs of TCEs from HCT116 cells transiently transfected as in a. d SIAH-2
expression levels are reported as FPKM reconstructed from Cufflinks RNA-Seq analysis from HCT116 transiently transfected with siControl or siChe-1
and exposed to hypoxia. e qRT–PCR performed as in b. Values were normalized to RPL19 mRNA expression. Error bars represent the standard error of
three different experiments. *P≤ 0,02, n.s., not significant
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through the activation and stabilization of the transcription
factor HIF-1α [6]. Its activity is mainly reflected in a
change of glucose metabolism, which switches from mito-
chondrial respiration to increased anaerobic glycolysis [33].
In this work we show how Che-1 plays an important
role in the adaptation of the cell to hypoxia. Indeed,
Che-1 results activated after hypoxic treatment in
HCT116 and HT29 cells (Fig. 1a), and its depletion in-
creases apoptosis following hypoxia, underlying the rele-
vance of Che-1 in cell survival (Fig. 1c and d). Our
group, as well as other researchers, has previously shown
how numerous types of stress affect the half-life of Che-
1, its localization and its functions [16–18]. These effects
are mediated through specific Che-1 phosphorylations
by DDR checkpoint kinases such as ATM, Chk2 and
MK2 [24]. Although hypoxia does not induce DDR, it
has been recently shown that it can still induce ATM ac-
tivity [34], leaving to assume that even in these stressful
conditions for the cell, this kinase may be responsible
for the phosphorylation and stabilization of Che-1. Not-
ably, unlike other cellular stresses such as genotoxic in-
sult [35], in response to hypoxic stress Che-1 is also
activated at the transcriptional level, especially during
the early hours (Fig. 1b). These findings suggest that
Che-1 may be a direct target of HIF-1α, but further
studies will be needed to confirm this hypothesis and to
characterize the mechanisms of this regulation.
Previous findings have demonstrated that hypoxia elicits
alterations in cell metabolism through several mechanisms
[36]. In this study we demonstrate an involvement of Che-
1 in cell metabolic adaptation upon hypoxic conditions.
Indeed, its depletion leads to an inhibition of the meta-
bolic switch observed in cells subjected to hypoxic treat-
ment (Fig. 2a and b). The relevance of the involvement of
Che-1 in cell adaption is confirmed by the evidence that
its depletion produces a markedly reduction of glucose
and glutamine consumption (Fig. 2c), associated with re-
duced inhibition of oxygen consumption (Fig. 2d) and
with less activation of glycolytic enzymes (Fig. 2e).
Hypoxia is one of the most important pathological
characteristics of solid tumors, and is clinically associ-
ated with a poor prognosis as it may adversely affect the
outcome of radiotherapy and chemotherapy [37, 38].
Another important feature of cancer cells is the high
Fig. 5 Model to explain Che-1 involvement in HIF-1α stabilization. Under hypoxic conditions the depletion of Che-1 leads to a decrease of the
ubiquitin E3 ligase SIAH2, allowing an increase of the prolyl isomerase PHD3. This results in a decrease of HIF-1α stabilization (bottom)
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glycolytic activity even in the presence of normal oxygen
level (Warburg effect) [39]. Our findings show how Che-
1, in presence of hypoxia, is required for the production
of primary metabolic substrates utilized from cancer
cells for ATP production and macromolecules biosyn-
thesis, needed for their proliferation and progression
[40]. Preliminary results have shown that Che-1 deple-
tion produces metabolic alterations in cancer cells even
in absence of the hypoxic stress, leading us to speculate
its possible role played in the Warburg effect [39, 41].
However, further experiments will be required to under-
stand the Che-1’s true role in these complex pathways.
Moreover, it also possible that the high levels of Che-1
observed in numerous tumor cell lines, not only contrib-
ute to cell proliferation, but also play an important role
in the metabolic adaptation of these cells.
Che-1 exerts its functions mainly as a coactivator of
transcription [14], and even in the case of cellular response
to hypoxic stress, its depletion produces a decrease in the
transcriptional activity of HIF-1α (Fig. 3). This might imply
a direct action of Che-1 on transcription along with this
transcriptional factor. However, although some preliminary
experiments showed the presence of Che-1 on the
promoters of genes regulated by HIF-1α (data not shown),
co-immunoprecipitation experiments have failed to demon-
strate the direct interaction between these two proteins.
Our results, however, show that Che-1 is required for
HIF-1α stabilization in response to hypoxia (Fig. 4a). In
fact, in Che-1 depleted cells there is a strong decrease in
the protein levels of this transcription factor but not of
its RNA messenger (Fig. 4b).
All this appears to be the result of a minor transcrip-
tion of SIAH-2 (Fig. 4c and d), necessary for the degrad-
ation of PHD3 [30]. This transcriptional downregulation
of SIAH2 by Che-1 increase PHD-3 availability during
hypoxia, providing a negative feedback mechanism for
HIF-1α stability (Fig. 5). Evidently, we cannot rule out
that Che-1 may either adjust the levels of HIF-1α also
through other mechanisms, or affect the metabolism
triggering other pathways. Indeed, only future studies
will be able to shed light on these aspects.
Conclusion
In conclusion, our data from these studies reveal a novel
role for Che-1 as molecular determinant in the response
to hypoxia of colorectal cancer cells. The ability of Che-1
to regulate HIF1-α stabilization, provides a novel meta-
bolic target for tumor treatment.
Additional files
Additional file 1: Figure S1. Che-1 is involved in the metabolic switch in
response to hypoxia. A- and B- HT29 (A) and A549 (B) cells were transiently
transfected with stealth siRNA negative control (siControl) or siRNA Che-1
(siChe-1) and exposed to hypoxia for 16 h where indicated and pH was
measured. C- and D- Score plots indicating metabolic differences between
hypoxic and normoxic samples from HT29 (C) and A549 (D) cells transiently
transfected as in A. E- HT29 cells were transfected as in A and the medium
lactate content was evaluated. (TIF 5841 kb)
Additional file 2: Figure S2. Che-1 regulates genes transcription in
response to hypoxia. A- Quantitative RT–PCR (qRT–PCR) for metabolic genes
expression was performed in HT29 cells transiently transfected with Stealth
siRNA negative control (siControl) or siRNA Che-1 (siChe-1) and exposed to
hypoxia for 4 h. Values were normalized to RPL19 mRNA expression. Error
bars represent the standard error of three different experiments. *P = 0,0010,
**P≤ 0,0003, ***P≤ 0,004, n.s., not significant. (TIF 1835 kb)
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